As per the agreement, UCB has acquired Lectus drug discovery and development programmes targeting ion channels used to treat specific set of Central Nervous System (CNS) indications.
UCB has also gained rights to market products discovered from the use of Lectus’s proprietary Leptics technology for a number of further ion channel targets.
UCB will use Lectus’s Leptics technology to identify compounds in a new area of chemical space.
Such new compounds developed will possess a novel mechanism of action mediated through an effect on ion channel accessory proteins, UCB claims.
UCB New Medicines president Ismail Kola said Lectus’s drug discovery and development programmes support their research efforts in the CNS field.
"I feel confident it will enable us to further honour our commitment to deliver scientific research driven by the patient’s needs," Kola said.